Skip to main content

Drug Safety

liver.jpg

Methotrexate and hepatic fibrosis: we must be doing something right

Dec 02, 2021

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in rheumatology, and the consequent frequency of patient counselling about it, relatively little

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

Nov 30, 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
ICYMI: Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the #ACR21 annual meeting.https://t.co/SQOLQRmQtp https://t.co/ZA1uISdGyk
Dr. John Cush @RheumNow( View Tweet )
Nov 28, 2021
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Nov 24, 2021

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
The Last CBD Trial: Dr. David Liew ( @drdavidliew) discusses abstract #1456 presented at the #ACR21 annual meeting.https://t.co/Kw3h2vTJkv https://t.co/WZGV7iOFlA
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
covid vaccine needle vaccination

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE

It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 



It is worth noting that the Phase III randomised

Read Article
This podcast is devoted to discussing patient satisfaction and factors important in their willingness or unwillingness (resistance) to change therapies. https://t.co/eVLlD8gEIM https://t.co/B24NWnGLHu
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
ICYMI: Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/9VbCJse6Tr

Dr. John Cush @RheumNow( View Tweet )

Nov 21, 2021
RheumNow Podcast square

RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)

Nov 19, 2021

Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription.. But you later find out they did not change, did not fill the prescription.  Why were

Read Article
PSA2L.jpg

An Old Friend – Methotrexate in Psoriatic Arthritis

Nov 16, 2021

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been

Read Article
heart.jpg (keep)

Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kayhttps://t.co/GtMtUh33QE https://t.co/yjJngF25Y4
Dr. John Cush @RheumNow( View Tweet )
Nov 12, 2021
iv.infusion.jpg

Can "Ultra-low" dose Rituximab work for RA?

Nov 11, 2021

The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.

Read Article
audience learn

Day 4 Report from ACR21

Nov 10, 2021

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
Retrospective chart review of rheumatic irAE patients: Persistent rheumatic irAE activity 🔼received GC Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
Abst 1517 Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE - Most common rheumatic IRAE = inflammatory arthritis - Higher prevalence of ANA in those tx w/ chemo prior to ICI #ACR21 @RheumNow https://t.co/7qgogSMjUr
Akhil Sood MD @AkhilSoodMD( View Tweet )
Nov 09, 2021
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

Nov 09, 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?



The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of

Read Article
#ACR21 Ab#1941: ORAL Surveillance VTE risk ▶️Tofa 10 BID risk > 5 BID > TNFi for VTE, DVT, PE ▶️Age, male, obesity, HTN, h/o VTE, oral contraception/HRT, steroids, antidepressants were risk factors @RheumNow https://t.co/JOKNyYVZfX https://t.co/mTkgkwPIT6
Nov 09, 2021
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA) ▶️Pooled data does not show ⬆️ risk of CVD ▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors Less clear than oral surveillance data, but concerns in those w riskshttps://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc
Nov 09, 2021
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
Nov 09, 2021
×